Provided by Tiger Trade Technology Pte. Ltd.

PMV Pharmaceuticals

1.24
-0.0200-1.59%
Post-market: 1.240.00000.00%19:30 EDT
Volume:576.32K
Turnover:710.86K
Market Cap:66.29M
PE:-0.88
High:1.29
Open:1.26
Low:1.20
Close:1.26
52wk High:1.88
52wk Low:1.02
Shares:53.46M
Float Shares:51.66M
Volume Ratio:0.32
T/O Rate:1.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4131
EPS(LYR):-1.4800
ROE:-70.93%
ROA:-42.39%
PB:0.93
PE(LYR):-0.84

Loading ...

PMV Pharmaceuticals Prices Oversubscribed $50.8 Million Offering

TIPRANKS
·
Sep 02

U.S. Stocks on the MOVE-GoPro, TXNM Energy, Emergent BioSolutions

Reuters
·
Sep 01

Craig-Hallum Sticks to Their Buy Rating for PMV Pharmaceuticals (PMVP)

TIPRANKS
·
Sep 01

U.S. Stocks on the MOVE-Robinhood Markets, Park Hotels & Resorts, Capricor Therapeutics

Reuters
·
Sep 01

Top Premarket Decliners

MT Newswires Live
·
Sep 01

Oncology Firm PMV Pharma Falls on $51 Mln Stock-and-Warrants Sale

Reuters
·
Sep 01

PMV Pharmaceuticals 42M share Spot Secondary priced at $1.21

TIPRANKS
·
Sep 01

Press Release: PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

Dow Jones
·
Sep 01

PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering

MT Newswires Live
·
Sep 01

PMV Pharmaceuticals Highlights Promising Phase 2 Ovarian Data

TIPRANKS
·
Sep 01

Oncology Co PMV Pharma Drops After Beginning Equity Offering

Reuters
·
Sep 01

PMV Pharmaceuticals announces updated ovarian cancer data from PYNNACLE trial

TIPRANKS
·
Sep 01

PMV Pharmaceuticals announces common stock, warrants offering

TIPRANKS
·
Sep 01

PMV Pharma Launches Underwritten Public Offering of Common Stock, Warrants

Reuters
·
Sep 01

PMV Pharma Announces Proposed Public Offering of Securities

THOMSON REUTERS
·
Sep 01

PMV Pharma Says Rezatapopt Posts 46% Response Rate in Phase 2 Platinum-Resistant Ovarian Cancer Trial

Reuters
·
Sep 01

PMV Pharmaceuticals, - Median Time to Response 1.3 Months, Median Duration of Response 10.0 Months

THOMSON REUTERS
·
Sep 01

PMV Pharmaceuticals, - Rezatapopt Shows Favorable Safety Profile with 5% Discontinuation Rate Due to Adverse Events

THOMSON REUTERS
·
Sep 01

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data from Pynnacle Phase 2 Pivotal Trial

THOMSON REUTERS
·
Sep 01

PMV Pharmaceuticals Q2 EPS USD -0.34

Reuters
·
Aug 14